The Experts below are selected from a list of 150 Experts worldwide ranked by ideXlab platform

Francoise Dignatgeorge - One of the best experts on this subject based on the ideXlab platform.

  • Circulating Endothelial Cells a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease
    Circulation, 2009
    Co-Authors: David M Smadja, Laetitia Mauge, D Israelbiet, Francoise Dignatgeorge, Pascal Vouhe, Gabriella Agnoletti, Severine Peyrard, Pascale Gaussem, Damien Bonnet, Marilyne Levy
    Abstract:

    BACKGROUND: Congenital heart disease can be complicated by pulmonary arterial hypertension (PAH), the reversibility of which is often difficult to predict. We recently reported a lung biopsy study showing impaired apoptotic regulation of Endothelial Cells in irreversible PAH. The objective of the present study was to identify noninvasive biomarkers of Endothelial turnover that could be used to identify congenital heart disease patients at risk of irreversible PAH. METHODS AND RESULTS: Circulating Endothelial Cells (CECs) isolated with CD146-coated beads and Circulating CD34(+)CD133(+) progenitor Cells (CPCs) were quantified in peripheral vein, pulmonary artery, and pulmonary vein blood samples from 26 patients with congenital heart disease (16 with reversible PAH [median age 2 years] and 10 with irreversible PAH [median age 9 years]) and 5 control patients. Surgical lung biopsy was performed in 19 cases. As expected, Endothelial remodeling was observed in irreversible PAH but not in reversible PAH. CEC and CPC numbers were each similar in the 3 types of blood samples. CEC numbers were significantly higher in patients with irreversible PAH (median 57 CEC/mL) than in patients with reversible PAH and control subjects (median 3 CEC/mL in the 2 groups). In contrast, CPC numbers did not differ among patients with irreversible or reversible PAH and control subjects (median 84, 64, and 44 CPC/10(5) lymphocytes, respectively, in the 3 groups). CONCLUSIONS: Irreversible PAH in congenital heart disease is associated with Endothelial damage and with increased Circulating Endothelial Cell counts. The present study suggests that CECs could be a valuable tool to define therapeutic strategies in congenital heart disease patients with PAH.

  • Circulating Endothelial Cell count as a diagnostic marker for non st elevation acute coronary syndromes
    Circulation, 2004
    Co-Authors: Jacques Quilici, Nathalie Banzet, Philippe Paule, Jeanbaptiste Meynard, Murielle Mutin, J L Bonnet, Pierre Ambrosi, Jose Sampol, Francoise Dignatgeorge
    Abstract:

    Background— Shedding of Endothelial Cells from damaged endothelium into the blood occurs in a variety of vascular disorders. The purpose of this study was to evaluate the utility of Circulating Endothelial Cell (CEC) count as a diagnostic marker of non–ST-elevation acute coronary syndromes (ACSs). Methods and Results— CEC counts were determined immediately (H0), 4 hours (H4), and 8 hours (H8) after admission in 60 patients with documented non–ST-elevation ACS and 40 control patients with no evidence of coronary artery disease. A total of 32 patients in the ACS group had elevated CEC counts (>3 Cells/mL) in relation to early admission and single-episode chest pain. Patients from the control group had normal CEC counts. The interval between the chest pain episode and elevation was significantly shorter for CEC than troponin I. No correlation was found between the 2 markers. Interestingly, a subgroup of ACS patients with initially normal troponin I levels had high CEC counts, thus allowing early diagnosis in...

Klaas Hoekman - One of the best experts on this subject based on the ideXlab platform.

  • increased numbers of small Circulating Endothelial Cells in renal Cell cancer patients treated with sunitinib
    Angiogenesis, 2009
    Co-Authors: Laura Vroling, Astrid A M Van Der Veldt, Richard R De Haas, John B A G Haanen, Gerrit Jan Schuurhuis, D J Kuik, Hester Van Cruijsen, Henk M W Verheul, Alfons J M Van Den Eertwegh, Klaas Hoekman
    Abstract:

    Mature Circulating Endothelial Cell (CEC) as well as Endothelial progenitor populations may reflect the activity of anti-angiogenic agents on tumor neovasculature or even constitute a target for anti-angiogenic therapy. We investigated the behavior of CECs in parallel with hematopoietic progenitor Cells (HPCs) in the blood of renal Cell cancer patients during sunitinib treatment. We analyzed the kinetics of a specific population of small VEGFR2-expressing CECs (CD45neg/CD34bright), HPCs (CD45dim/CD34bright), and monocytes in the blood of 24 renal Cell cancer (RCC) patients receiving 50 mg/day of the multitargeted VEGF inhibitor sunitinib, on a 4-week-on/2-week-off schedule. Blood was taken before treatment (C1D1), on C1D14, C1D28, and on C2D1 before the start of cycle 2. Also plasma VEGF and erythropoietin (EPO) were determined. Remarkably, while CD34bright HPCs and monocytes decreased during treatment, CD34bright CECs increased from 69 Cells/ml (C1D1) to 180 Cells/ml (C1D14; P = 0.001) and remained high on C1D28. All Cell populations recovered to near pre-treatment levels on C2D1. Plasma VEGF and EPO levels were increased on C1D14 and partly normalized to pre-treatment levels on C2D1. In conclusion, opposite kinetics of two Circulating CD34bright Cell populations, HPCs and small CECs, were observed in sunitinib-treated RCC patients. The increase in CECs is likely caused by sunitinib targeting of immature tumor vessels.

Valerie Boige - One of the best experts on this subject based on the ideXlab platform.

  • clinical value of Circulating Endothelial Cell levels in metastatic colorectal cancer patients treated with first line chemotherapy and bevacizumab
    Annals of Oncology, 2012
    Co-Authors: David Malka, Valerie Boige, N Jacques, Nadege Vimond, A Adenis, Eveline Boucher, J Y Pierga, Thierry Conroy, Bruno Chauffert
    Abstract:

    BACKGROUND We investigated whether Circulating Endothelial Cells (CECs) predict clinical outcome of first-line chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC) patients. PATIENTS AND METHODS In a substudy of the randomized phase II FNCLCC ACCORD 13/0503 trial, CECs (CD45- CD31+ CD146+ 7-amino-actinomycin- Cells) were enumerated in 99 patients by four-color flow cytometry at baseline and after one cycle of treatment. We correlated CEC levels with objective response rate (ORR), 6-month progression-free survival (PFS) rate (primary end point of the trial), PFS, and overall survival (OS). Multivariate analyses of potential prognostic factors, including CEC counts and Kohne score, were carried out. RESULTS By multivariate analysis, high baseline CEC levels were the only independent prognostic factor for 6-month PFS rate (P < 0.01) and were independently associated with worse PFS (P = 0.02). High CEC levels after one cycle were the only independent prognostic factor for ORR (P = 0.03). High CEC levels at both time points independently predicted worse ORR (P = 0.025), 6-month PFS rate (P = 0.007), and PFS (P = 0.02). Kohne score was the only variable associated with OS. CONCLUSION CEC levels at baseline and after one treatment cycle may independently predict ORR and PFS in mCRC patients starting first-line bevacizumab and chemotherapy.

  • bevacizumab in patients pts with advanced hepatoCellular carcinoma hcc preliminary results of a phase ii study with Circulating Endothelial Cell cec monitoring
    Journal of Clinical Oncology, 2007
    Co-Authors: David Malka, C Dromain, Francoise Farace, S Horn, J P Pignon, Michel Ducreux, Valerie Boige
    Abstract:

    4570 Background: Effective therapy for pts with advanced HCC is still lacking. This phase II trial was designed to define efficacy of bevacizumab in HCC pts. Methods: Pts with unresectable HCC rece...

Robert S Kerbel - One of the best experts on this subject based on the ideXlab platform.

Francesco Bertolini - One of the best experts on this subject based on the ideXlab platform.

  • the multifaceted Circulating Endothelial Cell in cancer towards marker and target identification
    Nature Reviews Cancer, 2006
    Co-Authors: Francesco Bertolini, Patrizia Mancuso, Yuval Shaked, Robert S Kerbel
    Abstract:

    The number of Circulating Endothelial Cells and their progenitors is increased in some types of cancer, and there is evidence that aspects of these Cells might correlate with clinical outcome of cancer patients treated with anti-angiogenic drugs.

  • continuous infusion of endostatin inhibits differentiation mobilization and clonogenic potential of Endothelial Cell progenitors
    Clinical Cancer Research, 2003
    Co-Authors: Manuela Capillo, Patrizia Mancuso, Alberto Gobbi, Silvia Monestiroli, Giancarlo Pruneri, Chiara Dellagnola, Giovanni Martinelli, Leonard D Shultz, Francesco Bertolini
    Abstract:

    Purpose: We investigated the effect of endostatin on differentiation, mobilization, and clonogenic potential of Circulating Endothelial Cell (EC) progenitors, and whether the effect of endostatin was improved by continuous infusion (CI) versus bolus administration. Experimental Design: Four-color flow cytometry and clonogenic EC cultures were used to study EC progenitors in tumor-free mice, tumor-bearing immunodeficient mice, and immunodeficient mice xenotransplanted with human bone marrow (BM) Cells. Results: Endostatin significantly reduced the number of Circulating EC progenitors in tumor-free BALB/c mice. The effect of endostatin on EC progenitors was enhanced significantly in mice treated with CI drug treatment. When immunodeficient mice xenotransplanted with human BM Cells were treated with CI of endostatin we observed a significant decrease in the engraftment and differentiation of human BM-derived EC progenitors. Numbers of Circulating EC progenitors increased 7-fold in immunodeficient mice bearing human lymphoma. In this preclinical model, treatment with CI of endostatin inhibited host murine EC progenitor mobilization and human tumor growth. Furthermore, the clonogenic potential of EC progenitors was impaired severely. Conclusions: Endostatin is a potent inhibitor of the mobilization and clonogenic potential of human and murine EC progenitors, and its preclinical activity is increased significantly in CI compared with bolus administration. These observations might be useful in the design of future clinical trials.